Non-Alcoholic Steatohepatitis Biomarkers Market 2022-2027: Analysis on the Basis of Current Industry Demand, Growth Rate, New Trends and Key Players
Market Highlights
The Global Non-Alcoholic
Steatohepatitis Biomarkers Market is Expected to Register a CAGR of 20.92%
and is Anticipated to Reach USD 1,960.4 Million by 2024. Non-alcoholic
steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD),
which is characterized by liver inflammation and damage caused by a buildup of
fat in the liver. Currently, there are no noninvasive diagnostic tools approved
for non-alcoholic steatohepatitis.
Growing prevalence of NASH, increasing demand for
non-invasive diagnostic tests, and rising initiatives for creating awareness
are some major factors propelling the growth of the market. Additionally, the
rising prevalence of diabetes and obesity is likely to support market growth.
On the hand, the presence of stringent regulations by the US FDA for the
qualification of biomarkers is anticipated to restrict the market growth during
the assessment period.
Get Sample Report: https://www.marketresearchfuture.com/sample_request/7984
Segment Analysis
The global non-alcoholic steatohepatitis biomarkers market
has been segmented by into type and end user. By type, the market has been
segmented into serum biomarkers, hepatic fibrosis biomarkers, apoptosis
biomarkers, oxidative stress biomarkers, and others. By end user, the market
has been segmented into pharmaceutical companies and CROs, research institutes
and academics, hospitals & clinics, diagnostic centers, and others.
Market Players
Market Research Future (MRFR) recognizes the following
companies as the key players in the global non-alcoholic steatohepatitis
biomarkers market that includes are BioPredictive (France), Celerion (US),
Cisbio (France), Echosens (France), Enterome (France), GENFIT (France),
Laboratory Corporation of America Holdings (US), NGM Biopharmaceuticals (US),
One Way Liver, SL (Spain), Pacific Biomarkers (US), Prometheus Laboratories Inc
(US), Perspectrum Diagnostics Ltd (UK), Quest Diagnostics, Regulus
Therapeutics, Inc. (US), Siemens Healthineers (Germany), Shenzhen New
Industries Biomedical Engineering Co., Ltd (China), and Xeptagen SpA (Italy)
Access Report Details @ https://www.marketresearchfuture.com/reports/non-alcoholic-steatohepatitis-biomarkers-market-7984
Regional Analysis
Geographically, the Americas is expected to dominate the
global non-alcoholic steatohepatitis biomarkers market. The growth in this
region can be attributed to the favorable government initiatives, the presence
of sophisticated healthcare infrastructure, and rising prevalence of diabetes,
fatty liver disease, and obesity. Europe is anticipated to hold the second
position in the global market owing to the factors such as growing incidence of
NASH, increasing prevalence of obesity and diabetics, and increasing research
and development on liver diseases. In the Asia-Pacific region, the market
growth is mainly due to the factors such as the presence of a large patient
base, increase in healthcare spending, and availability of skilled healthcare
personnel. The Middle East and Africa is anticipated to register the lowest
share in the global market. In the African region, the market is likely to be
negatively affected by factors such as poor healthcare infrastructure, less
disposable income, limited awareness about liver diseases, including NASH.
Key Findings of the Study:
·
Global Non-Alcoholic Steatohepatitis Biomarkers
Market is projected to reach USD 1,960.4 million by 2024 with 92% CAGR during
the review period of 2019 to 2024.
·
Americas accounted for the largest share in the
region due to the growing demand of non-invasive diagnostics for NASH.
·
The pharmaceutical companies and CROs segment
accounted for the largest share, holding a market value of USD 226.7 million in
2018.
About US:
Market Research Future (MRFR), enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,
5Th Floor, New York,
New York 10013
Comments
Post a Comment